Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences
PR Newswire•01/10/2026•08:02 ET
0
Key Highlights
- ➤CEO Kelvin Cooper to attend three October industry conferences
- ➤Cooper presents Nu-3 preclinical data poster at IDWeek October 22
- ➤ThinkEquity presentation covers Nu-3 antimicrobial compound for diabetic foot ulcers
Expert Statements
Kelvin Cooper, CEO of Lakewood-Amedex Biotherapeutics
“Nu-3 – A Novel, Broad Spectrum Antimicrobial Compound with High In- Vitro Activity Against Resistant Pathogens for the Treatment of Infected Diabetic Foot Ulcers.”
Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences PR Newswire
SARASOTA, Fla., Oct. 1, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics, Inc. (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced that CEO Kelvin Cooper, Ph.D., will participate in three upcoming industry conferences.
Get started
Create a free account to read the full story.